Researchers developed a protein that enhances CAR T-cell therapy by boosting anticancer activity and promoting the development of memory CAR T-cells for long-term immune protection against cancer.
CAR T-cell therapy approved in 2017 reprograms immune cells with a chimeric antigen receptor to recognize and attack cancer cells, successfully clearing cancer cells in some patients but fading over time.
The boost in CAR T-cell therapy seeks to address the issue of fading numbers post initial treatment, which leads to cancer recurrence in patients over time.
The researchers' advancement in CAR T-cell therapy has not been tested yet and holds promise in overcoming the shortfalls like fading effectiveness in current therapies.
[
Collection
]
[
|
...
]